Fda D.i.s.c.o. Burst Edition: Lorbrena For Patients With Metastatic Non-Small Cell L...

FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell l...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Imjudo (tremelimumab) in combination with Imfinzi (...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for ...

U.S. Food and Drug Administration

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Lytgobi (futibatinib) for adult patients with previ...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or met...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory ...

U.S. Food and Drug Administration

FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer

U.S. Food and Drug Administration

FDA approved Rybrevant and Lazcluze for patients with non-small cell lung cancer | Chemo-free trt

Pharmacist and Drugs

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Lorlatinib for ALK+metastatic non-small cell lung cancer.

OncBrothers: Practice-Changing Cancer Discussions

FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLC

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

FDA Approves Capmatinib for Advanced Lung Cancer

UCLA Jonsson Comprehensive Cancer Center

FDA Approval of Durvalumab for Stage III Unresectable NSCLC

FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More

Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC

FDA Approval in NSCLC, Priority Review in SCLC, 2018 SABCS Highlights, and More